KBC Group NV Has $59.14 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

KBC Group NV boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 13.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 896,162 shares of the medical research company’s stock after acquiring an additional 104,499 shares during the quarter. KBC Group NV owned 0.15% of Edwards Lifesciences worth $59,137,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of EW. Cetera Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 175.1% during the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock valued at $3,640,000 after buying an additional 24,242 shares during the last quarter. BDF Gestion acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $5,148,000. Tidal Investments LLC lifted its holdings in shares of Edwards Lifesciences by 54.7% during the 1st quarter. Tidal Investments LLC now owns 30,245 shares of the medical research company’s stock valued at $2,890,000 after buying an additional 10,700 shares during the last quarter. Raymond James & Associates lifted its holdings in shares of Edwards Lifesciences by 2.8% during the 2nd quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock valued at $168,597,000 after buying an additional 50,124 shares during the last quarter. Finally, AIA Group Ltd lifted its holdings in shares of Edwards Lifesciences by 91.7% during the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after buying an additional 358,556 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 4.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,250 shares of company stock valued at $2,744,438. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of several analyst reports. Canaccord Genuity Group reduced their target price on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a report on Friday, October 25th. The Goldman Sachs Group reduced their target price on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a report on Friday, July 26th. Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Baird R W lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Finally, Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $66.15 on Friday. The firm has a market cap of $39.02 billion, a PE ratio of 9.55, a PEG ratio of 3.70 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a fifty day moving average price of $67.42 and a 200 day moving average price of $76.44.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.59 EPS. Research analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.